With pressure to “publish or perish,” some scientists fake their research results. Elisabeth Bik spends her days correcting them.
With better questions, many reproducibility problems will fall away, says Paul Smaldino.
Launched in 2013 as a non-profit community service, the bioRxiv server has brought preprint practice to the life sciences and recently posted its 64,000th manuscript… Rapid dissemination via bioRxiv is also encouraging new initiatives that experiment with the peer review process and the development of novel approaches to literature filtering and assessment.
In 1973, Rosenhan published the paper “On Being Sane in Insane Places” in the prestigious journal Science, and it was a sensation. The study, in which eight healthy volunteers went undercover as “pseudopatients” in 12 psychiatric hospitals across the country, discovered harrowing conditions that led to national outrage…
Fifty years later, I tried to find out how Rosenhan had convinced his subjects to go undercover as psychiatric patients and discovered a whole lot more. Yes, Rosenhan had charm. He had charisma. He had chutzpah to spare. And, as I eventually uncovered, he was also not what he appeared to be.
… the diagnosticity of statistical tests depend entirely on how well statistical models map onto underlying theories, and so improving statistical techniques does little to improve theories when the mapping is weak. There is also little reason to expect that preregistration will spontaneously help researchers to develop better theories (and, hence, better methods and analyses).
Cleared-tissue axially swept light-sheet microscopy (ctASLM) enables high-speed, refraction index-independent imaging of live, cleared and expanded samples with isotropic, submicron resolution.
New work on the problem of “scissors congruence” explains when it’s possible to slice up one shape and reassemble it as another.
Thirty years after scientists discovered the defective gene that causes cystic fibrosis, two new trials show a therapy could help 90 percent of patients. The FDA approved the triple drug, Trikafta, five months ahead of its deadline.